Telix Pharmaceuticals Limited (TLX) shares rose 6.90 percent, gaining $0.68 to $10.46 on Friday, after the company announced that the U.S. Food and Drug Administration accepted its resubmitted New Drug Application for TLX101-Px.
The stock is currently trading at $10.46 compared with its previous close of $9.78, after opening at $10.10 on the Nasdaq. Shares traded between $10.10 and $10.71 during the session, with volume at 195,550 shares versus an average daily volume of 247,896.
The FDA acceptance includes a PDUFA target action date of September 11, 2026, for the investigational PET imaging agent designed to detect glioma, a form of brain cancer. The candidate has already received Fast Track and Orphan Drug designations, highlighting its potential to address unmet needs in neuro-oncology imaging. Telix's 52-week range is $6.28 to $20.00.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.